On August 29, 2023 Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") reported that a new U.S. patent which covers CAMCEVI (leuprolide mesylate) and its labeled indication is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as "the Orange Book" (Press release, Foresee Pharmaceuticals, AUG 29, 2023, View Source [SID1234634766]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 8, 2023, the United States Patent and Trademark Office (USPTO) issued U.S. patent No. 11,717,555 B2, under the title "Pharmaceutical Compositions Having a Selected Release Duration", which has extended the patent protection on CAMCEVI to January 1, 2039. The formulation patent covers not only CAMCEVI but also Foresee’s other LHRH products in development.

The listing of the patent brings the total number of Orange Book-listed patents from three to four.

"We are excited to further strengthen our intellectual property protection for CAMCEVI and other developing LHRH products with the newly granted patent," said Dr. Ben Chien, Foresee’s Chairman and CEO. "Additionally, this serves as another milestone to validate our SIF technologies and to potentially bring in more commercial value through the extended patent life and royalty terms."